The Pharmacogenetics of Aripiprazole-Induced Hyperprolactinemia: What Do We Know?

Click to increase image sizeClick to decrease image size

Author contributions

D Koller drafted the manuscript. F Abad-Santos critically revised the manuscript.

Financial & competing interests disclosure

D Koller is cofinanced by the H2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant. F Abad-Santos has been a consultant or an investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, Cinfa, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva, and Zambon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

D Koller is cofinanced by the H2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant. F Abad-Santos has been a consultant or an investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, Cinfa, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva, and Zambon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.